A new survey suggests that 83% of peptide-aware Americans want the FDA to make peptides more accessible. The survey, conducted by Hone Health, found that many Americans are already using peptides as a health and wellness tool, despite the lack of a clear prescription pathway.

What are Peptides?

Peptides are short chains of amino acids that can have various health benefits. The seven peptides under review by the FDA are BPC-157, TB-500, KPV, MOTS-c, Emideltide (DSIP), Semax, and Epitalon. These peptides are often sold online with labels such as “for research use only,” but many consumers are using them for human use, which can be risky due to the lack of regulation.

According to Abid Husain, M.D., a triple-board-certified physician specializing in peptide therapy, the current situation is not safe for consumers. “Right now, most people can’t get these compounds in a safe, controlled manner, so they get them however they can,” says Husain. “And that means putting themselves at exceptional risk.”

FDA Review

The Pharmacy Compounding Advisory Committee (PCAC) will consider whether the seven peptides should be added to the 503A Bulks List. If included, licensed pharmacists and physicians can use them in patient-specific compounded prescriptions. This would provide a safer pathway for consumers and allow doctors to prescribe appropriate doses and monitor treatment.

The FDA will consider the committee’s advice as well as public comments before making a final decision. If the FDA moves these peptides to the 503A Bulks List, it doesn’t mean that they are approved as drugs, but it would allow physicians to prescribe them for various uses, including athletic or cognitive performance.

Original reporting: El Paso News (HLL/CB) — read the source article.